<?xml version="1.0" encoding="utf-8"?>
<XML>
<JOURNAL>
<YEAR>2024</YEAR>
<VOL>16</VOL>
<NO>3</NO>
<MOSALSAL>0</MOSALSAL>
<PAGE_NO>85</PAGE_NO>


<ARTICLES>

	<ARTICLE> 
		<TitleF>Mesenteric Vein Thrombosis (MVT) as the Cause of Abdominal Pain in Pediatric Cystic Fibrosis (CF): A Case Report</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background: Cystic fibrosis (CF) represents a prevalent autosomal recessive condition that predominantly impacts the respiratory and gastrointestinal systems. Abdominal pain in patients with cystic fibrosis is commonly linked to conditions including distal intestinal obstruction syndrome, pancreatitis, or hepatic disease. This case report presents a rare etiology of abdominal pain, specifically mesenteric vein thrombosis (MVT) attributed to hereditary thrombophilia, observed in a pediatric patient diagnosed with cystic fibrosis (CF).
Case Presentation: A 3-year-old female patient with a confirmed diagnosis of cystic fibrosis, established through a sweat chloride test, exhibited significant right lower quadrant (RLQ) abdominal pain. The initial diagnostic evaluation, comprising an abdominal series, laboratory assessments, and abdominal ultrasound, ruled out prevalent etiologies including DIOS, pancreatitis, and appendicitis. The presence of persistent pain necessitated additional diagnostic evaluation through a contrast-enhanced CT scan, which subsequently identified mesenteric vein thrombosis. The analysis of genetic testing revealed a homozygous mutation in the MTHFR C677T gene, which is suggestive of hereditary thrombophilia. These findings were corroborated through Sanger sequencing methodologies.
Conclusion: This case highlights the importance of evaluating uncommon conditions such as mesenteric vein thrombosis in pediatric patients with cystic fibrosis who exhibit atypical abdominal pain. An extensive diagnostic strategy, incorporating genetic analysis, is crucial for the prompt identification and focused intervention necessary to avert significant complications. Abdominal pain is a significant clinical symptom that may be associated with various underlying conditions, including cystic fibrosis, venous thrombosis, and mesenteric ischemia. Each of these conditions presents unique challenges in diagnosis and management, necessitating a comprehensive understanding of their pathophysiology and clinical implications.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>1</FPAGE>
			<TPAGE>7</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/31
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/5/10
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/23
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/7/2
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Arya</Name>
				<MidName></MidName>
				<Family>Behzadi</Family>
				<NameE>Arya</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Behzadi</FamilyE>
				<Organizations>
				<Organization>School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>aryabehzadi1377@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Pooya</Name>
				<MidName></MidName>
				<Family>Poormehr</Family>
				<NameE>Pooya</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Poormehr</FamilyE>
				<Organizations>
				<Organization>School of medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>pooya.poormehr@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Nazanin</Name>
				<MidName></MidName>
				<Family>Farahbakhsh</Family>
				<NameE>Nazanin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Farahbakhsh</FamilyE>
				<Organizations>
				<Organization>Department of Pediatric Pulmonology, Mofid Pediatrics Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>naznin26farabakhsh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Abdominal Pain</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Cystic Fibrosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Venous thrombosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Mesenteric Ischemia</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Branfield S, Washington AV. Control the platelets, control the disease: A novel cystic fibrosis hypothesis. J Thromb Haemost. 2020 Jul;18(7):1531-4.##Döring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, et al. Clinical trials in cystic fibrosis. In: Journal of Cystic Fibrosis. 2007. p. 85-99.##Knight-Perry J, Branchford BR, Thornhill D, Martiniano SL, Sagel SD, Wang M. Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors. Thromb Res [Serial online]. 2017 Oct;158(May):161-6 (6 screens). Available from: http://dx.doi.org/10.1016/j.thromres.2017.08.022##Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest [Serial online]. 2021 Oct 1;160(4):1232-40 (9 screens). Available from: https://pubmed.ncbi.nlm.nih.gov/34147501/##Konrad J, Eber E, Stadlbauer V. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatr Respir Rev [Serial online]. 2022 Jun 1;42:9-16 (8 screens). Available from: https://pubmed.ncbi.nlm.nih.gov/33485777/##Scott JA, Barry PJ, Jones AM, Athwal VS. Management of superior mesenteric venous thrombus in cystic fibrosis related liver disease. Paediatr Respir Rev [serial online]. 2020 Sep;35:106-108 (3 screens). Available from : 10.1016/j.prrv.2020.04.007. Epub 2020 Apr 21.##Mavilia M. Distal intestinal obstructive syndrome (DIOS): a gastrointestinal complication of cystic fibrosis in adults. Clin J Gastroenterol [serial online]. 2019;12(6):571-573 (3 screens).Available from : 10.1007/s12328-019-00979-7.##Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol [serial online]. 2017;2017:1-9 (9 screens). Available from : 10.1155/2017/5128760##Lusman SS, Grand R. Approach to chronic abdominal pain in Cystic Fibrosis. J Cyst Fibros [serial online]. 2017 Nov;16 Suppl 2:S24-S31 (8 screens). Available from: https://linkinghub.elsevier.com/retrieve/pii/S1569199317308111##Dracea LL, Vida LC, Patran OC. Appendicitis in Cystic Fibrosis: A Challenging Diagnosis. Bulletin of the Transilvania University of Brasov [serial online]. 2020 Dec 30;13 (62)(2):19-26 (7 screens). Available from : http://webbut.unitbv.ro/index.php/Series_VI/article/view/535##Lindberg U, Svensson L, Hellmark T, Segelmark M, Shannon O. Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status. Thromb Res [serial online]. 2018 Feb;162(November 2017):32-7 (6 screens). Available from:##Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: An update. Pediatr Pulmonol [serial online]. 2018;53(S3):S30-S50 (21 screens). Available from : 10.1002/ppul.24129##Samoyedny A, Sajja S, Ratnasekera A. Idiopathic acute mesenteric venous thrombosis causing ischemic enteritis: A case report. Int J Surg Case Rep [serial online]. 2020;74:247-250 (4 screens). Available from : 10.1016/j.ijscr.2020.08.030##Arora K, Naren AP. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Curr Drug Targets. 2016;17(11):1275-81.##Spicuzza L, Sciuto C, Di Dio L, Mattina T, Leonardi S, del Giudice MM, et al. Mild cystic fibrosis in patients with the rare P5L CFTR mutation. J Cyst Fibros. 2012 Jan;11(1):30-3.##Handschick M, Hedtfeld S, Tümmler B. Frequency of the hyperactive W493R ENaC variant in carriers of a CFTR mutation. J Cyst Fibros. 2012 Jan;11(1):53-5.##Freswick PN, Reid EK, Mascarenhas MR. Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. Nutrients. 2022 Mar 23;14(7):1341.##Anıl H, Kılıç Yıldırım G, Harmancı K, Bozkurt Turhan A, Akay OM, Bör Ö, et al. Thromboelastogram as a Tool to Predict Hypercoagulability in Children With Cystic Fibrosis. Clin Appl Thromb. 2018 Mar;24(2):348-52.##McGivern TJ, Molloy K, Bahar M, McElvaney NG, Moran N, Kerrigan SW. A platelet dense-granule secretion defect may lead to a muted inflammatory cell mobilization response in cystic fibrosis patients. J Thromb Haemost [serial online]. 2013;11(10):1939-1942 (4 screens). Available from : 10.1111/jth.12377##Marteyn BS, Burgel P-R, Meijer L, Witko-Sarsat V. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. Front Cell Infect Microbiol. 2017;7:243.##Rimessi A, Bezzerri V, Patergnani S, Marchi S, Cabrini G, Pinton P. Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis. Nat Commun [serial online]. 2015;6:6201 (16 screens). Published 2015 Feb 4. Available from : 10.1038/ncomms7201##Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. Front Pediatr. 2018;6:142.##Balfour-Lynn IM, Malbon K, Burman JF, Davidson SJ. Thrombophilia in children with cystic fibrosis. Pediatr Pulmonol. 2005;39.##Williams V, Griffiths ABM, Sci BM, Yap ZL, Martin J, Smith G, et al. Increased Thrombophilic Tendency in Pediatric Cystic Fibrosis Patients. :71-6.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Management of Hypoxia in the Simultaneous Presentation of Sickle Cell Trait and Cystic Fibrosis. Exploring a Rare Case with a Comprehensive Review</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background: Cystic fibrosis (CF) is an inheriting disorder that has a strong impact on the pulmonary systems of individuals, as a result, hypoxia might be presented among patients who have CF. In addition, hypoxia is a pathological condition that might be present among patients with sickle cell trait (SCT). However, the simultaneous presentation of both SCT and CF in a patient is rare.
Case presentation: A 7-year-old boy came to the hospital with a chief complaint of cyanosis and cough. In his physical examination, he has low SpO2. His fiber-optic bronchoscopy depicted purulent secretion in the main bronchus. As well, his sweet chloride test was above 80 mmol/L. Thus, by the impression of CF exacerbation, he got HARD treatment and antibiotics. Additionally, during hospitalization, SCT as another impression was diagnosed for him.
Conclusion: Although the co-existence of CF and SCT is rare among patients. The physicians must consider both CF and SCT when a child comes to the emergency room with hypoxia.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>8</FPAGE>
			<TPAGE>13</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/13
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/5/23
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/23
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/7/2
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Seyed Ahmad</Name>
				<MidName></MidName>
				<Family>Tabatabaii</Family>
				<NameE>Seyed Ahmad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Tabatabaii</FamilyE>
				<Organizations>
				<Organization>Department of Pediatric Pulmonology, Mofid Pediatrics Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>ahmadtabatabaii@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Neda</Name>
				<MidName></MidName>
				<Family>Entezari Farahabadi</Family>
				<NameE>Neda</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Entezari Farahabadi</FamilyE>
				<Organizations>
				<Organization>Department of Pediatric Pulmonology, Mofid Pediatrics Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>neda93farahabadi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Cystic fibrosis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Sickle cell trait</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Hypoxia</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Rafeeq MM, Murad HAS. Cystic fibrosis: current therapeutic targets and future approaches. J Transl Med. 2017;15(1):84.##De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109(5):893-9.##Bergeron C, Cantin AM. Cystic Fibrosis: Pathophysiology of Lung Disease. Semin Respir Crit Care Med. 2019;40(6):715-26.##Montgomery ST, Mall MA, Kicic A, Stick SM. Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies. Eur Respir J. 2017;49(1).##Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. The Lancet. 2010;376(9757):2018-31.##Beaudet AL, Perciaccante RG, Cutting GR. Homozygous nonsense mutation causing cystic fibrosis with uniparental disomy. American journal of human genetics. 1991;48(6):1213.##Spence J, Perciaccante R, Greig G, Willard H, Ledbetter D, Hejtmancik JF, et al. Uniparental disomy as a mechanism for human genetic disease. American journal of human genetics. 1988;42(2):217.##Sobush KT, Thornburg CD, Voynow JA, Davis SD, Peterson-Carmichael SL. A 2-year-old girl with co-inherited cystic fibrosis and sickle cell-β+ thalassemia presenting with recurrent vaso-occlusive events during cystic fibrosis pulmonary exacerbations: a case report. J Med Case Rep. 2013;7:203.##Porter RC, Cloutier MM, Brasfield DM, Mangos JA, Miale T, Tiller RE. Cystic fibrosis in two black children with sickle cell anemia. 1979.##Amendola G, Garvin J, Piomelli S. Cystic fibrosis in a black child with hemoglobin SD disease. Journal of Pediatric Hematology/Oncology. 1990;12(3):340-2.##Warwick AB, Haver K, Rosoff PM. Homozygous sickle cell disease and cystic fibrosis in an adolescent. Pediatric pulmonology. 1998;26(3):224-7.##https://doi.org/10.1002/(SICI)1099-0496(199809)26:33.0.CO;2-2##Banjar HH. Cystic fibrosis: presentation with other diseases, the experience in Saudi Arabia. Journal of Cystic Fibrosis. 2003;2(3):155-9.##Needleman JP, Franco ME, Varlotta L, Reber‐Brodecki D, Bauer N, Dampier C, et al. Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease. Pediatric pulmonology. 1999;28(6):418-22.##https://doi.org/10.1002/(SICI)1099-0496(199912)28:63.0.CO;2-D##D'Aloya N. Sleep related upper airway obstruction and hypoxaemia in sickle cell disease. Archives of Disease in Childhood. 1993;68(5):715.##Samuels MP, Stebbens VA, Davies SC, Picton-Jones E, Southall DP. Sleep related upper airway obstruction and hypoxaemia in sickle cell disease. Archives of Disease in Childhood. 1992;67(7):925-9.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>A Patient with Splenomegaly and Systemic Lupus Erythematosus Diagnosed with Lymphoma: A Case Report and Systematic Literature Review</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Systemic Lupus Erythematosus (SLE) is one of these conditions that presents difficult hurdles since it is a multi-systemic autoimmune condition with a wide range of implications, including an increased risk of cancer among affected people. According to recent evidence, it has been revealed that the lymphoma rate in patients with SLE can be 4 to 7 times higher than that of the general population. This increased risk is to be emphasized through stringent and attentive screening and management as the mechanism of this risk is still under research. Therefore, this section discusses a case study and literature regarding SLE and lymphoma better to comprehend the intricate correlation between the two conditions. Here, we present the case of a 53-year-old male who was just diagnosed with SLE and also suffering from abdominal pain and distention, in which the diagnosis of lymphoma is made via serial investigations. This case, therefore, gives us a lesson on the fact that Lymphoma should be considered as one of the differential diagnoses in SLE patients presenting with abdominal complaints. With the ever-changing knowledge about the basic mechanisms of SLE and appropriate screening techniques, our attention to cancer risk in SLE patients should be increased to achieve better clinical outcomes.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>14</FPAGE>
			<TPAGE>22</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/2
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/4/12
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/17
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/27
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Raja</Name>
				<MidName></MidName>
				<Family>Adib Bakhsh</Family>
				<NameE>Raja</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Adib Bakhsh</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>rajaa_bakhsh09@outlook.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Khaled</Name>
				<MidName></MidName>
				<Family>Saleh Dairi</Family>
				<NameE>Khaled</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Saleh Dairi</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Khaled_Saleh_Dairi12@outlook.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mohammad</Name>
				<MidName></MidName>
				<Family>Hamid Alabdali</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Hamid Alabdali</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>mohammad_hamid_alabdali12@outlook.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Sameer</Name>
				<MidName></MidName>
				<Family>Mohammed Aljuhani</Family>
				<NameE>Sameer</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammed Aljuhani</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>SameerMohammedAljuhani@outlook.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Rawan</Name>
				<MidName></MidName>
				<Family>Khaled Altaib</Family>
				<NameE>Rawan</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Khaled Altaib</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>RawanKhaledAltaib15@outlook.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mohammed</Name>
				<MidName></MidName>
				<Family>Ahmed Hasaballah</Family>
				<NameE>Mohammed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ahmed Hasaballah</FamilyE>
				<Organizations>
				<Organization>King Faisal Hospital, Internal Medicine Department, 4588, Prince Majed ibn Abd Al Aziz, 7451, Al Maabdah, Makkah 24236, Saudi Arabia.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>MohammedAhmedHasaballah@outlook.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Systemic Lupus Erythematosus</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Lymphoma</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Vasculitis</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Autoimmune</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Abdominal Manifestation</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Gergianaki, I. and G. Bertsias, Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner. Frontiers in medicine, 2018. 5: p. 161.##Pavli, P., et al., Acute abdominal situations as presenting or flaring manifestations of systemic lupus erythematosus: a case series. Mediterranean Journal of Rheumatology, 2022. 33(3): p. 339.##Mounir, B., et al., Acute intestinal obstruction in systemic lupus Erythematosus: Case report and review of the literature. Global Journal of Rare Diseases, 2023. 8(1): p. 001-005.##Chen, L., et al., Clinical features of lupus enteritis: a single-center retrospective study. Orphanet journal of rare diseases, 2021. 16: p. 1-8.##Yulistiawati, F., A case report of a woman with SLE and lupus enteritis as the first manifestation of active systemic lupus erythematosus. Bali Medical Journal, 2023. 12(2): p. 1321-1237.##Frittoli, R.B., et al., Gastrointestinal involvement in systemic lupus erythematosus: A systematic review. Journal of translational autoimmunity, 2021. 4: p. 100106.##Paramaiswari, A., A. Kusumawati, and D.B. Nugroho, Severe Abdominal Pain and Multi-Organ Involvement in a Young Woman With Systemic Lupus Erythematosus. Journal of Medical Cases, 2023. 14(6): p. 196.##Barile-Fabris, L., M. Hernández-Cabrera, and J. Barragan-Garfias, Vasculitis in systemic lupus erythematosus. Current rheumatology reports, 2014. 16: p. 1-6.##Miyagawa, F., et al., A case of systemic lupus erythematosus with cutaneous leukocytoclastic vasculitis mimicking bullous SLE. Case Reports in Dermatology, 2022. 13(3): p. 464-469.##Kallas, R., D. Goldman, and M.A. Petri, Cutaneous vasculitis in SLE. Lupus Science &#38; Medicine, 2020. 7(1): p. e000411.##Gheita, T., et al., Cutaneous vasculitis in systemic lupus erythematosus patients: potential key players and implications. Lupus, 2018. 27(5): p. 738-743.##Klein, A., A. Polliack, and A. Gafter-Gvili, Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leukemia research, 2018. 75: p. 45-49.##Ladouceur, A., et al., Cancer and systemic lupus erythematosus. Rheumatic Disease Clinics, 2020. 46(3): p. 533-550.##Martín-López, M., et al., Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. Rheumatology, 2023. 62(1): p. 217-224.##Shaharir, S. and C. Gordon, Constitutional symptoms and fatigue in systemic lupus erythematosus, in Systemic Lupus Erythematosus. 2016, Elsevier. p. 317-324.##Iwamuro, M., et al., Intestinal Diffuse Large B-Cell Lymphoma in a Patient with Systemic Lupus Erythematosus. Case Reports in Gastrointestinal Medicine, 2020. 2020.##Qattan, M.Y., The Incidence Rate of Non-Hodgkin's Lymphoma in Saudi Arabia: An Observational Descriptive Population Based Epidemiological Study from the Saudi Cancer Registry (2006-2016). Open Access Macedonian Journal of Medical Sciences, 2023. 11(B): p. 445-452.##Song, L., et al., The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Arthritis research &#38; therapy, 2018. 20: p. 1-13.##Saadoun, D., et al., Expansion of autoreactive unresponsive CD21−/low B cells in Sjögren's syndrome-associated lymphoproliferation. Arthritis &#38; Rheumatism, 2013. 65(4): p. 1085-1096.##Boddu, P., et al., SLE and non-Hodgkin's lymphoma: a case series and review of the literature. Case Reports in Rheumatology, 2017. 2017.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Assessing Neutrophil CD64 Expression: A Key Biomarker for Diagnosing Infections and Evaluating Antibiotic Therapy in Acute Leukemia Patients</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Introduction: Patients with acute leukemia (AL) are at an increased risk of infection, particularly in acute or critical situations, where timely identification of the cause of infection is crucial. While traditional methods such as microbial cultures remain the gold standard, they require 24&#8211;48 hours for results. In recent years, novel biomarkers like neutrophil CD64 expression have been widely investigated as indicators of infection. However, the diagnostic utility of CD64 within the clinical context of AL patients, especially those who are neutropenic and undergoing treatment, has not been extensively studied. Therefore, this study aimed to assess the diagnostic potential of neutrophil CD64 expression in monitoring the progression of infection and evaluating antibiotic therapy in AL patients complicated by infection.
Methods: Forty AL patients (20 in the infection group and 20 in the non-infection group), along with 40 healthy controls, were recruited. Data on the percentage of neutrophil CD64+ (%CD64+), CD64 index, C-reactive protein (CRP), white blood cell (WBC) count, and absolute neutrophil count (ANC) were collected.
Results: Patients with infection exhibited higher %CD64+, CD64 index, and CRP levels compared to those without infection (p&#60;0.001). The sensitivity of both %CD64+ and the CD64 index in diagnosing infection was 90%, while their specificities were 83.3% and 86.7%, respectively. Furthermore, in the infection group, both %CD64+ and the CD64 index were significantly down-regulated after effective antibiotic therapy (p&#60;0.001).
Conclusion: CD64 shows significant promise in enhancing diagnostic precision and in assessing the effectiveness of antibiotic therapy in AL patients.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>23</FPAGE>
			<TPAGE>31</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/22
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/5/1
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/23
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/7/2
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Alreza</Name>
				<MidName></MidName>
				<Family>Mohebbi</Family>
				<NameE>Alreza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohebbi</FamilyE>
				<Organizations>
				<Organization>Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>reza.mhb96@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Najmaldin</Name>
				<MidName></MidName>
				<Family>Saki</Family>
				<NameE>Najmaldin</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Saki</FamilyE>
				<Organizations>
				<Organization>Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>najmaldinsaki@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Hossein</Name>
				<MidName></MidName>
				<Family>Karimpourian</Family>
				<NameE>Hossein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Karimpourian</FamilyE>
				<Organizations>
				<Organization>Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>dr-hossein-k@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Shaban</Name>
				<MidName></MidName>
				<Family>Alizadeh</Family>
				<NameE>Shaban</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Alizadeh</FamilyE>
				<Organizations>
				<Organization>Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Tehran University of Medical sciences, Tehran, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>alizadehs@sina.tums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>CD64 index</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Infection</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Acute leukemia</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Antibiotic therapy</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.##Hansen, B.A., et al., Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment. Mediterr J Hematol Infect Dis, 2020. 12(1): p. e2020009.##Tebbi, C.K., Etiology of Acute Leukemia: A Review. Cancers (Basel), 2021. 13(9).##Crawford, J., D.C. Dale, and G.H. Lyman, Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 2004. 100(2): p. 228-37.##KVI, R., - Infections in Patients with Acute Leukemia. Infections in Hematology, 2014. 27: p. 3-23.##Logan, C., D. Koura, and R. Taplitz, Updates in infection risk and management in acute leukemia. Hematology Am Soc Hematol Educ Program, 2020. 2020(1): p. 135-139.##Kern, W.V., et al., Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis, 2005. 24(2): p. 111-8.##Fihman, V., et al., Stenotrophomonas maltophilia--the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect, 2012. 64(4): p. 391-8.##Lai, C.C., et al., Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. J Antimicrob Chemother, 2011. 66(6): p. 1374-82.##Freifeld, A.G., et al., Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis, 2011. 52(4): p. e56-93.##Fontela, P.S., S. O'Donnell, and J. Papenburg, Can biomarkers improve the rational use of antibiotics? Curr Opin Infect Dis, 2018. 31(4): p. 347-352.##Larsen, F.F. and J.A. Petersen, Novel biomarkers for sepsis: A narrative review. Eur J Intern Med, 2017. 45: p. 46-50.##García-Salido, A., et al., Accuracy of CD64 expression on neutrophils and monocytes in bacterial infection diagnosis at pediatric intensive care admission. Eur J Clin Microbiol Infect Dis, 2019. 38(6): p. 1079-1085.##Rogina, P., et al., Neutrophil CD64 molecule expression can predict bloodstream infection in septic shock patients. Clin Chem Lab Med, 2017. 55(6): p. e130-e132.##Yang, A.P., et al., Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis. Clin Chem Lab Med, 2016. 54(2): p. 345-51.##Ye, Z., et al., Diagnostic performance of neutrophil CD64 index in patients with sepsis in the intensive care unit. J Int Med Res, 2019. 47(9): p. 4304-4311.##Gros, A., et al., The sensitivity of neutrophil CD64 expression as a biomarker of bacterial infection is low in critically ill patients. Intensive Care Med, 2012. 38(3): p. 445-52.##Gao, Y., et al., Neutrophil CD64 index as a superior indicator for diagnosing, monitoring bacterial infection, and evaluating antibiotic therapy: a case control study. BMC Infectious Diseases, 2022. 22(1): p. 892.##Hung, S.K., et al., Current Evidence and Limitation of Biomarkers for Detecting Sepsis and Systemic Infection. Biomedicines, 2020. 8(11).##Liu, Y., et al., Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis. Springerplus, 2016. 5(1): p. 2091.##Hamade, B. and D.T. Huang, Procalcitonin: Where Are We Now? Crit Care Clin, 2020. 36(1): p. 23-40.##Tan, M., et al., The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem, 2019. 120(4): p. 5852-5859.##Vassallo, M., et al., Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in Patients With Solid Tumors. Front Med (Lausanne), 2021. 8: p. 627967.##Guo, J., et al., [Diagnostic Value of CD64(+) Index of Neutrophils for Patients with Leukemia Combined with Early Infection]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2016. 24(5): p. 1375-1378.##Dai, J., et al., Neutrophil CD64 as a diagnostic marker for neonatal sepsis: Meta-analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2017. 26(2): p. 327-332.##Qin, D.J., et al., [Value of combined determination of neutrophil CD64 and procalcitonin in early diagnosis of neonatal bacterial infection]. Zhongguo Dang Dai Er Ke Za Zhi, 2017. 19(8): p. 872-876.##Liang, J., et al., Neutrophil CD64: a potential biomarker for the diagnosis of infection in patients with haematological malignancies. Hematology, 2021. 26(1): p. 970-975.##Guo, X.Y., Y.K. Kang, and S.X. Guo, [Comparison of Diagnosis Values of CD64 Infection Index, CRP, PCT and NEU% in the Leukemia Complicated with Bacterial Infection]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2018. 26(1): p. 132-135.##Sack, U., CD64 expression by neutrophil granulocytes. Cytometry Part B: Clinical Cytometry, 2017. 92(3): p. 189-191.##Standage, S.W. and H.R. Wong, Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther, 2011. 9(1): p. 71-9.##Wang, X., et al., Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. Crit Care, 2015. 19(1): p. 245.##Yeh, C.F., et al., Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care, 2019. 9(1): p. 5.##Hao-Min Lan, C.C.W., Su-Hsun Liu, Chih-Huang Li, Yu-Kang Tu, Kuan-Fu Chen, Biomarkers in Diagnosis of Sepsis and Infection: A Systematic Review and Bayesian Network Meta-Analysis. SSRN Electron. J., 2019.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>IGF Gene Family Expression: A Comparative Study in Acute Myeloid Leukemia (AML) and Healthy Bone Marrow</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background: &#160;One of the most common types of leukemia is acute myeloid leukemia (AML). Intrinsic and extrinsic factors may lead to AML. Insulin-like growth factor (IGF) is a mitogenic intermediate from the liver that regulates growth and proliferation in response to GH. In this study, we examined the expression of IGF family genes in bone marrow of AML patients (M3 and Non-M3) and compared them with normal samples.
Methods: Forty bone marrow samples from recently diagnosed AML patients along with 15 samples from subjects without hematological malignancies were collected. For molecular tests, RNA extraction and cDNA synthesis were performed. Finally, IGF1, IGF2, IGFBP3, IGF1R, and IGF2R gene expression were examined by Real-Time PCR.
Results: IGF1, IGF1R, and IGFBP3 gene expression were significantly increased in patients with AML. In contrast, IGF2 and IGF2R genes did not show significant expression changes between the two groups.
Conclusion: The expression in this gene family soared in AML patients&#39; bone marrow, compared to normal subjects. This can be caused by malignant cells in the bone marrow. These malignant cells express proteins that increase the number of malignant cells. Moreover, they can be considered as diagnostic biomarkers or therapeutic targets with further research.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>32</FPAGE>
			<TPAGE>39</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/1
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/4/11
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/29
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/8
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Mohammadreza</Name>
				<MidName></MidName>
				<Family>Moonesi</Family>
				<NameE>Mohammadreza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moonesi</FamilyE>
				<Organizations>
				<Organization>Tabriz University of Medical Sciences, Tabriz, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>mr.moonesi@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Hanie</Name>
				<MidName></MidName>
				<Family>Mehdizade</Family>
				<NameE>Hanie</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mehdizade</FamilyE>
				<Organizations>
				<Organization>Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Hanie.mehdizade@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Saeed</Name>
				<MidName></MidName>
				<Family>Zakakhosravi</Family>
				<NameE>Saeed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Zakakhosravi</FamilyE>
				<Organizations>
				<Organization>Tabriz University of Medical Sciences, Tabriz, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>s.z.khosravi73@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Samira</Name>
				<MidName></MidName>
				<Family>Molaei Ramshe</Family>
				<NameE>Samira</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Molaei Ramshe</FamilyE>
				<Organizations>
				<Organization>Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>samirdokht20@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mehdi</Name>
				<MidName></MidName>
				<Family>Allahbakhshian</Family>
				<NameE>Mehdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Allahbakhshian</FamilyE>
				<Organizations>
				<Organization>Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>allahbakhshian@sbmu.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Saeed</Name>
				<MidName></MidName>
				<Family>Solali</Family>
				<NameE>Saeed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Solali</FamilyE>
				<Organizations>
				<Organization>Tabriz University of Medical Sciences, Tabriz, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Saeedsolali@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Majid</Name>
				<MidName></MidName>
				<Family>Farshdousti hagh</Family>
				<NameE>Majid</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Farshdousti hagh</FamilyE>
				<Organizations>
				<Organization>Tabriz University of Medical Sciences, Tabriz, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>mfarshdoustihagh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>IGF Family</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Leukemia</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>AML</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>IGF1</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>IGFBP3</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Bullinger, L., K. Döhner, and H. Döhner, Genomics of acute myeloid leukemia diagnosis and pathways. Journal of clinical oncology, 2017. 35(9): p. 934-946.##Masaeli, M., A. Bahrami, and M. Shahabian, Association between urban benzene pollution and incidence of acute myeloid leukemia. Iranian Journal of Blood and Cancer, 2018. 10(2): p. 50-55.##Moonesi, M., et al., IGF family effects on development, stability, and treatment of hematological malignancies. Journal of Cellular Physiology, 2021. 236(6): p. 4097-4105.##Moonesi, M., et al., Comparison of High-Resolution Melting (HRM) Analysis with Direct Sequencing for the Detection of DNMT3A Mutations in AML Patients. Asian Pacific Journal of Cancer Prevention: APJCP, 2022. 23(7): p. 2185.##Hao, T., et al., An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Scientific reports, 2019. 9(1): p. 12070.##Ghasemi, A., et al., Methylation status of SOX17 and RUNX3 genes in acute leukemia. Iranian Journal of Blood and Cancer, 2015. 7(5): p. 213-219.##Hauke, R.J. and S.R. Tarantolo, Hematopoietic growth factors. Laboratory Medicine, 2000. 31(11): p. 613-615.##Yazdani, Z., et al., IL‐35, a double‐edged sword in cancer. Journal of cellular biochemistry, 2020. 121(3): p. 2064-2076.##Khosravi, S.Z., et al., Rapid detection of N-RAS gene common mutations in acute myeloid leukemia (AML) using high resolution melting (HRM) method. Asian Pacific Journal of Cancer Prevention: APJCP, 2022. 23(1): p. 125.##Mimeault, M., et al., Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of cellular and molecular medicine, 2007. 11(5): p. 981-1011.##Russell, N., Autocrine growth factors and leukaemic haemopoiesis. Blood reviews, 1992. 6(3): p. 149-156.##Chapuis, N., et al., Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. haematologica, 2010. 95(3): p. 415.##Resnicoff, M., et al., Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Laboratory Investigation; a Journal of Technical Methods and Pathology, 1993. 69(6): p. 756-760.##Velloso, C., Regulation of muscle mass by growth hormone and IGF‐I. British journal of pharmacology, 2008. 154(3): p. 557-568.##Vincent, A.M. and E.L. Feldman, Control of cell survival by IGF signaling pathways. Growth hormone &#38; IGF research, 2002. 12(4): p. 193-197.##Hakuno, F. and S.-I. Takahashi, 40 years of IGF1: IGF1 receptor signaling pathways. Journal of molecular endocrinology, 2018. 61(1): p. T69-T86.##Yakar, S., et al., Circulating levels of IGF-1 directly regulate bone growth and density. The Journal of clinical investigation, 2002. 110(6): p. 771-781.##Brismar, K., et al., Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. The Journal of Clinical Endocrinology &#38; Metabolism, 1994. 79(3): p. 872-878.##https://doi.org/10.1210/jcem.79.3.7521354##Laviola, L., A. Natalicchio, and F. Giorgino, The IGF-I signaling pathway. Current pharmaceutical design, 2007. 13(7): p. 663-669.##Pollak, M.N., E.S. Schernhammer, and S.E. Hankinson, Insulin-like growth factors and neoplasia. Nature Reviews Cancer, 2004. 4(7): p. 505-518.##Rashidi, A. and G.L. Uy, Targeting the microenvironment in acute myeloid leukemia. Current hematologic malignancy reports, 2015. 10: p. 126-131.##Ayer, M., et al., Evaluation of Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Expression Levels in Patients with Chronic Lymphocytic Leukemia. Turkish Journal of Hematology, 2016. 33(4): p. 335.##Zhang, J.-M., et al., ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer letters, 2019. 442: p. 193-201.##Karmali, R., et al., Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leukemia &#38; Lymphoma, 2015. 56(11): p. 3135-3142.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Evaluation of the CpG-island DNA Methylation Pattern in Promoter of DNMT1 and CDX2 Genes in Different Phases of Acute Myeloid Leukemia; A Follow-up Study</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background: Aberrant DNA methylation is a key epigenetic alteration observed in multiple cancers. Acute myeloid leukemia (AML), a prominent form of hematopoietic cancer, is characterized by abnormal proliferation and differentiation of myeloid progenitor cells. This study focuses on examining the methylation status of the CpG islands in the DNMT1 and CDX2 promoter regions and exploring their correlation with prognostic hematological laboratory parameters across three phases of AML: newly diagnosed, undergoing treatment, and in remission.
Material and methods: This follow-up case-control study recruited 11 new cases of confirmed AML admitted to Shariati Hospital in Tehran. All patients received AML treatment according to FDA protocol. The samples (peripheral blood) were collected before medication (new case phase), during medication (under treatment phase), and in the remission phase. Then, genomic DNA was extracted and treated with the bisulfite treatment method. Then, methylation-specific PCR (MSP) was conducted to amplify treated DNAs using two methylated and unmethylated primers related to their promoters&#39; DNMT1 and CDX2 CpG- islands. All statistical analysis was performed using SPSS v.25.
Results: The results of the methylation pattern of DNMT1 gene promoter CpG islands in the present study show that the hemimethylated pattern of the DNMT1 gene promoter is predominant in control (100%), new case phase (90.9%), under treatment phase (72.7%), and remission phase (100%). In the case of the CDX2 gene, the unmethylated pattern is predominant in control (57.14%), new case phase (72.7%), under-treatment phase (90.9%), and remission phase (81.8%). These differences were not statistically significant. No methylated pattern was observed in the control group, and different phases of AML were used for DNMT1 and CDX2. Also, the methylation status of DNMT1 and CDX2 were not correlated with prognostic hematological laboratory parameters.
Conclusion: The methylation patterns of CDX2 and DNMT1 are not different in healthy individuals and AML patients, as well as in different phases of AML. Also, the methylation patterns of CDX2 and DNMT1 cannot help determine the prognosis of AML patients through changes in hematological laboratory parameters.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>40</FPAGE>
			<TPAGE>47</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/12024/08/13
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/5/23
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/292024/09/17
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/27
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Saeed</Name>
				<MidName></MidName>
				<Family>Turkmen</Family>
				<NameE>Saeed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Turkmen</FamilyE>
				<Organizations>
				<Organization>Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>amir9226012@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Neda</Name>
				<MidName></MidName>
				<Family>Karami chermahini</Family>
				<NameE>Neda</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Karami chermahini</FamilyE>
				<Organizations>
				<Organization>Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Karamicha@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Amirhosein</Name>
				<MidName></MidName>
				<Family>Maali</Family>
				<NameE>Amirhosein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Maali</FamilyE>
				<Organizations>
				<Organization>Department of Medical Biotechnology, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>maali.amirhosein@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mohammad Reza</Name>
				<MidName></MidName>
				<Family>Keramati</Family>
				<NameE>Mohammad Reza</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Keramati</FamilyE>
				<Organizations>
				<Organization>Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Keramati.MD@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mohammad Hossein</Name>
				<MidName></MidName>
				<Family>Ahmadi</Family>
				<NameE>Mohammad Hossein</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ahmadi</FamilyE>
				<Organizations>
				<Organization>Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Ahmadihossein@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Mehdi</Name>
				<MidName></MidName>
				<Family>Azad</Family>
				<NameE>Mehdi</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Azad</FamilyE>
				<Organizations>
				<Organization>Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Haematologicca@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Samaneh</Name>
				<MidName></MidName>
				<Family>Borouman-Noughabi</Family>
				<NameE>Samaneh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Borouman-Noughabi</FamilyE>
				<Organizations>
				<Organization>Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Samaneborouman@gmail.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>DNA methylation</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>DNMT1</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>CDX2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Acute Myeloid Leukemia</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Swaminathan M, Wang ES. Novel therapies for AML: a round-up for clinicians. Expert review of clinical pharmacology. 2020;13(12):1389-400.##Yeh W, Tirado C. Hypodiploidy in AML. Journal of the Association of Genetic Technologists. 2021;47(3):122-6.##Azad M, Bakhshi Biniaz R, Goudarzi M, Mobarra N, Alizadeh S, Nasiri H, et al. Short view of leukemia diagnosis and treatment in iran. Int J Hematol Oncol Stem Cell Res. 2015;9(2):88-94.##Maali A, Maroufi F, Sadeghi F, Atashi A, Kouchaki R, Moghadami M, Azad M. Induced pluripotent stem cell technology: trends in molecular biology, from genetics to epigenetics. Epigenomics. 2021;13(8):631-47.##Maali A, Atashi A, Ghaffari S, Kouchaki R, Abdolmaleki F, Azad M. A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future. Current stem cell research &#38; therapy. 2018;13(8):665-75.##Sahmani M, Vatanmakanian M, Goudarzi M, Mobarra N, Azad M. Microchips and their Significance in Isolation of Circulating Tumor Cells and Monitoring of Cancers. Asian Pac J Cancer Prev. 2016;17(3):879-94.##Zebardast S, Sahmani M, Mohammadi S, Foroughi F, Dehghani Fard A, Mohammadi Z, et al. The Gene Expression Profile and DNA Methylation Pattern of CDH1 and DNMT1 Genes in Acute Promyelocytic Leukemia (APL). Reports of biochemistry &#38; molecular biology. 2020;8(4):454-7.##Mohammadi Z, Azad M, Foroughi F, Khojastehpour S, Gheibi N, Samiee-Rad F, et al. Evaluation of expression level and methylation profile of CXX1 gene in breast cancer tissue blocks. Journal of cancer research and therapeutics. 2021;17(6):1328-34.##Maroufi F, Maali A, Abdollahpour-Alitappeh M, Ahmadi MH, Azad M. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy. Epigenomics. 2020;12(20):1845-59.##Karami N, Ahmadi MH, Mohammadi S, Maali A, Alizadeh A, Pishkhan Dibazar SH, Azad M. Methylation and Expression Status of The CpG-Island of SMG1 Promoter in Acute Myeloid Leukemia: A Follow-Up Study in Patients. Cell journal. 2022;24(4):163-9.##Amiri S, Atashi A, Azad M, Elmi A, Abbaszade Dibavar M, Ajami M, et al. Upregulation of Pro-inflammatory Cytokine Genes by Parvovirus B19 in Human Bone Marrow Mesenchymal Stem Cells. Biochem Genet. 2020;58(1):63-73.##Hoseini M, Sahmani M, Foroughi F, Khazaei Monfared Y, Azad M. Evaluating the Role of PTEN Promoter Methylation in Patients Predisposed to Hypercoagulable States via Methylation Specific PCR. Reports of biochemistry &#38; molecular biology. 2019;7(2):223-9.##Hojjatipour T, Sohani M, Maali A, Rostami S, Azad M. Aberrant DNA Methylation Status and mRNA Expression Level of SMG1 Gene in Chronic Myeloid Leukemia: A Case-Control Study. Cell journal. 2022;24(12):757-63.##Rahmani T, Azad M, Chahardouli B, Nasiri H, Vatanmakanian M, Kaviani S. Patterns of DNMT1 Promoter Methylation in Patients with Acute Lymphoblastic Leukemia. International journal of hematology-oncology and stem cell research. 2017;11(3):172-7.##Sohani M, Rostami S, Azad M, Hojjatipour T, Chahardouli B, Alizadeh S. Promoter Methylation Status and Expression Levels of RASSF1A Gene in Different Phases of Acute Lymphoblastic Leukemia (ALL). International journal of hematology-oncology and stem cell research. 2021;15(1):7-14.##Monzavi N, Zargar SJ, Gheibi N, Azad M, Rahmani B. Angiopoietin-like protein 8 (betatrophin) may inhibit hepatocellular carcinoma through suppressing of the Wnt signaling pathway. Iran J Basic Med Sci. 2019;22(10):1166-71.##Azad M, Kaviani S, Soleymani M, Nourouzinia M, Hajfathali A. Common polymorphism's analysis of thiopurine S-methyltransferase (TPMT) in Iranian population. 2009.##Najafi M, Alizadeh SA, Azad M, Naserpour Farivar T, Rajaei F, Hotam Sorouri K, et al. Effect of calprotectin subunit S100A9 on the expression and methylation of OCLN in human melanoma cell line A-375. Turkish journal of biology = Turk biyoloji dergisi. 2017;41(6):849-56.##Azad M, Kaviani S, Noruzinia M, Mortazavi Y, Mobarra N, Alizadeh S, et al. Gene Expression Status and Methylation Pattern in Promoter of P15INK4b and P16INK4a in Cord Blood CD34 (+) Stem Cells. Iranian journal of basic medical sciences. 2013;16(7):822-8.##Kim HJ, Seo EH, Bae DH, Haam K, Jang HR, Park JL, et al. Methylation of the CDX2 promoter in Helicobacter pylori-infected gastric mucosa increases with age and its rapid demethylation in gastric tumors is associated with upregulated gene expression. Carcinogenesis. 2020;41(10):1341-52.##Graule J, Uth K, Fischer E, Centeno I, Galván JA, Eichmann M, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clinical epigenetics. 2018;10(1):120.##Kawai H, Tomii K, Toyooka S, Yano M, Murakami M, Tsukuda K, Shimizu N. Promoter methylation downregulates CDX2 expression in colorectal carcinomas. Oncology reports. 2005;13(3):547-51.##Wang Y, Li Z, Li W, Liu S, Han B. Methylation of promoter region of CDX2 gene in colorectal cancer. Oncology letters. 2016;12(5):3229-33.##Wang Y, Li Z, Li W, Liu S, Han B. Methylation of CDX2 gene promoter in the prediction of treatment efficacy in colorectal cancer. Oncology letters. 2018;16(1):195-8.##Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172-9.##Aslani S, Mahmoudi M, Garshasbi M, Jamshidi AR, Karami J, Nicknam MH. Evaluation of DNMT1 gene expression profile and methylation of its promoter region in patients with ankylosing spondylitis. Clinical rheumatology. 2016;35(11):2723-31.##Thoene S, Rawat VP, Heilmeier B, Hoster E, Metzeler KH, Herold T, et al. The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia. 2009;23(4):649-55.##Khosravi A, Alizadeh S, Jalili A, Shirzad R, Saki N. The impact of Mir-9 regulation in normal and malignant hematopoiesis. Oncology reviews. 2018;12(1):348.##Darvishi M, Mashati P, Khosravi A. The clinical significance of CDX2 in leukemia: A new perspective for leukemia research. Leukemia research. 2018;72:45-51.##Makita K, Kitazawa R, Semba S, Fujiishi K, Nakagawa M, Haraguchi R, Kitazawa S. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus. World journal of gastroenterology. 2013;19(4):536-41.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Mapping of Favism and G6PD Disease in Iran: A Mini Review</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Hemolytic illness an interaction with Vicia fava, also referred to as fava beans, results in favism. This contact can happen in a few different ways: eating raw, cooked, or dried beans; walking through fields where V. fava is grown and possibly breathing in pollen; and introducing fava beans to a breastfed baby through their mother&#39;s milk. In populations, the illness is common. For example, it&#39;s typical to walk through fields that have been planted with fava in the northern Iranian provinces of Mazandaran and Guilan. This is a problem in areas where thalassemia is common since patients there frequently need blood transfusions. Although favism has a considerable economic impact, there is a limited number of particular statistics on this matter. This paper explores the implications of recent findings on favism and G6PD for the future.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>48</FPAGE>
			<TPAGE>54</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/12024/08/132024/06/21
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/4/1
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/292024/09/172024/09/13
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/23
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Ali</Name>
				<MidName></MidName>
				<Family>Davoudi Kiakalayeh</Family>
				<NameE>Ali</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Davoudi Kiakalayeh</FamilyE>
				<Organizations>
				<Organization>Department of Preventive and Social Medicine, School of Medicine, Guilan University of Medical Sciences. Rasht, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>davoudikiakalayeh@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Bahram</Name>
				<MidName></MidName>
				<Family>Darbandi</Family>
				<NameE>Bahram</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Darbandi</FamilyE>
				<Organizations>
				<Organization>Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>darbandi45@gums.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Sajad</Name>
				<MidName></MidName>
				<Family>Davoudi-kiakalayeh</Family>
				<NameE>Sajad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Davoudi-kiakalayeh</FamilyE>
				<Organizations>
				<Organization>Trauma Institute, Guilan University of Medical Sciences. Rasht, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>Sajad_davoudi2@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>G6PD</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Favism</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Vicia fava</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Iran</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Vogels IM, Van Noorden CJ, Wolf BH, Saelman DE, Tromp A, Schutgens RB, Weening RS. Cytochemical determination of heterozygous glucose-6-phosphate dehydrogenase deficiency in erythrocytes. Br J Haematol 1986; 63(2):402-5.##Shah SS, Diakite SA, Traore K, Diakite M, Kwiatkowski DP, Rockett KA, et al. A novel cytofluorometric assay for the detection and quantification of glucose6-phosphate dehydrogenase deficiency. Sci Rep 2012; 2:299.##Martini G, Toniolo D, Vulliamy T, Luzzatto L, Dono R, Viglietto G, et al. Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J 1986;5(8):1849-55.##Arese P, Mannuzzu L, Turrini F. Pathophysiology of favism. Folia Haematol Int Mag Klin Morphol Blutforsch 1989;116(5):745-52.##Caballero B, Food Intolerance, Encyclopedia of Human Nutrition. Third Edition, December 28, 2012.##Arese P, De Flora A. Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 1990; 27(1):1-40.##Cardador-Martinez A, Maya-Ocana K, Ortiz-Moreno A, et al. Effect of roasting and boiling on the content of vicine, convicine and L-3,4-dihydroxyphenylalanine in Vicia faba L. J Food Qual 2012;35:419-428.##Pulkkinen M, Zhou X, Lampi AM, Piironen V. Determination and stability of divicine and isouramil produced by enzymatic hydrolysis of vicine and convicine of faba bean. Food Chem 2016; 212:10-9.##Nagalla S. Besa EC, et al. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. Med scape. Jul 19, 2021. Available from: URL: https://emedicine.medscape.com/article/200390-overview?form=fpf##Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map. PLOS MEDICINE. 2012;9(11): e1001339.##Lauden SM, Chongwain S, Achidi A, Helm E, Cusick SE, Krug A, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in Cameroonian blood donors. BMC Research Notes 2019; 12(1): 195.##World Health Organization. Technical Consultation to Review the Classification of Glucose-6-Phosphate Dehydrogenase (G6PD). 25 &#38; 27 January 2022, virtual meeting. Available online: https://cdn.who.int/media/docs/ (accessed on 18 July 2022).##Salvati AM, Maffi D, Caprari P, Pasquino MT, Caforio MP, Tarzia A. Glucose-6-phosphate dehydrogenase deficiency and haemolytic agents. Ann. Ist. Super. Sanità .1999;35: 193-203.##Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol. Oncol. Clin 2016;30(2): 373-393.##Hwang DF, Chen TU, Toxins in Food: Naturally Occurring. Encyclopedia of Food and Health. 2016.##Karkanis A, Ntatsi G, Lepse L, Fernández JA, Vågen IM , Rewald B , et al. Faba Bean Cultivation - Revealing Novel Managing Practices for More Sustainable and Competitive European Cropping Systems. Front. Plant Sci. 02 August 2018(9) :1115.##Nelson DL, Cox MM. Lehninger Principles of Biochemistry (6th ed.). Basingstoke, England: Macmillan Higher Education. 13 February 2013. p. 576. ISBN 978-1-4641-0962-1.##Huheey JE, Martin DL. Malaria, favism and glucose-6-phosphate dehydrogenase deficiency. Experientia 1975; 31(10):1145-7.##Allahverdiyev AM, Bagirova M, Elcicek S, Cakir Koc R, Ates SC, SY Baydar, et al. Glucose-6-Phosphate Dehydrogenase Deficiency and Malaria: A Method to Detect Primaquine-Induced Hemolysis in vitro, intechopen.com. November 14th, 2012. DOI: 10.5772/48403##Arese P. How genetics and biology helped humanity to survive falciparum malaria Parassitologia 2006; 48(4):553-559.##Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A,Trang NT, Phuoc Long N, et al. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: A systematic review and meta-analysis Scientific Reports. 2017; 7: p. 45963.##Donoso G, Hedayat H, and Khayatian H. Favism, with special reference to Iran. Bull World Health Organ. 1969; 40(4): 513-519.##Beretta A, Manuelli M, Cena H, Favism: Clinical Features at Different Ages. Nutrients. 2023; 15(2): 343.##Meletis J, Konstantopoulos K. Favism - From the "avoid fava beans" of Pythagoras to the present. HAEMA 2004; 7(1):17.##Diegues A , Simões P , Ceriz T , Lopes A, Tomé E. Favism: A Case Report. Cureus. 2022; 14(3): e23269.##Hsia YE, Miyakawa F, Baltazar J, Ching NS, Yuen J, Westwood B, et al. Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii. Hum Genet 1993 Nov;92(5):470-6.##Jamerson BD , Haryadi TH, Bohannon A. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19? Archives of Medical Research . Volume 51, Issue 7, October 2020, Pages 743-744.##Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev. 2007 Sep;21(5):267-83. doi: 10.1016/j.blre.2007.05.002. Epub 2007 Jul 3.##G6PD Deficiency Is Associated with Significant Protection Against Severe, Life-threatening Malaria. Public Library of Science. March 13, 2007. Available from https://www.sciencedaily.com/releases/2007/03/070313114502.htm##Al-Allawi N, A Eissa A, Jubrael JMS, AR Jamal S, Hamamy H. Prevalence and molecular characterization of Glucose-6-Phosphate dehydrogenase deficient variants among the Kurdish population of Northern Iraq. BMC Blood Disord. 2010, 5:10:6. doi: 10.1186/1471-2326-10-6.##Belsey MA. The epidemiology of favism. Bull World Health Organ. 1973; 48(1):1-13.##Alavi naini A. Favism in Mazandaran , north of Iran. Iranian Journal of Public Health. 1997: Vol 26 No 3-4.##Kamali M,Taheri Sarvtin M. Investigating the Prevalence of Glucose - 6 -Phosphate Dehydrogenase (G6PD) Deficiency among Patients with Favism Symptoms in Kerman City, Southern Iran. International Journal of Medical Laboratory 2023 ;10 (2):173 -173.##Abolghasemi H, Mehrani H, Amid A. An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates. Clinical Biochemistry. 2004: Volume 37, Issue 3, Pages 241-244.##Nejadaria M, Mortazavi SM, Kohansal MH .Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency in Neonates Hospitalized in Pasteur Hospital of Bam, Iran. Medical Laboratory Journal, Mar-Apr, 2020; Vol 14: No 2.##Darbandi B, Zarezadeh S, Atrkar Roshan Z, Hassanzadeh Rad A, Baghersalimi A, The Efficacy of Vitamin E and Folic acid on the Acute Hemolysis Caused by Glucose-6 phosphate Dehydrogenase, Iran J Ped Hematol Oncol. 2017; Vol 7. No 3, 232-236.##Safaei Asl A, Emami S, Baghersalimi A, Darbandi B, Hassanzadeh Rad A, Badeli H. Normal saline, the known but least examined fluid therapy method for preventing heme induced nephropathy in children with glucose 6 phosphate dehydrogenase deficiency: a randomized controlled clinical trial. Pediatr Nephrol. 2023 Feb;38(2):549-555##https://doi.org/10.1007/s00467-022-05594-2##Jafari-Shakib A, Davoudi-Kiakalayeh A, Pour-Fathollah AA, Jafari-Shakib R, Mohtasham-Amiri Z. Health-related quality of life in beta thalassemia major children in north of Iran. Iranian Journal of Blood and Cancer. 2016; 8(4):108-111.##Mohtasham-Amiri Z, Khanaki K, Davoudi-Kiakalayeh A, Rezvani SM, Jafari-Shakib A, Jafari-Shakib R. Analysis of survival in patients with beta-thalassemia major in Guilan Northern Iran. Iranian Journal of Blood and Cancer.2018; 10(3):82-86.##Homaie Rad, E, Hajizadeh M, Rezaei S, Reihanian A, Ehsani- Chimeh E, Davoudi- Kiakalayeh A. Utilization and expenditures on traditional and herbal medicines in Iran: 2009-2016. Journal of Herbal Medicine.2021; 25:100414.##Davoudi-Kiakalayeh, A, Dalal, K, Yousefzade-Chabok, S, Jansson, B, Mohammadi, R. Costs related to drowning and near drowning in northern Iran (Guilan province).Ocean and Coastal Management, 2011; 54(3): pp. 250-255.##Tabari-Khomeiran, R, Ehsani-Chimeh, E, Davoudi Kiakalayeh, A, Homaie Rad, E, Delavari, S. Inequity in the distribution of rural family physicians in Iran: a cross sectional study. International Journal of Human Rights in Healthcare. 2019; 12(4): pp. 258-266.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Impact of SARS-CoV-2 on Oncogenesis: A Deep Dive into the COVID-19 and Cancer Nexus</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Background: The COVID-19 pandemic, triggered by the SARS-CoV-2 virus, has posed significant global health challenges, notably affecting individuals with pre-existing conditions like cancer. This review aims to provide an overview of current evidence regarding the bidirectional relationship between COVID-19 and cancer, focusing on potential mechanisms driving this association.
Search Strategy: A systematic search of the PubMed, Scopus, and Web of Science databases was conducted to identify studies published between January 2020 and March 2024. Articles were selected based on their relevance to the topic and adherence to rigorous methodological standards.
Results: Research indicates a complex interaction between COVID-19 and cancer, with clinical data highlighting variations in cancer diagnosis, prognosis, and treatment efficacy during SARS-CoV-2 infection. Mechanistic studies suggest that immune system dysregulation, chronic inflammation, and possible viral-induced cellular changes may contribute to cancer progression. Additionally, the pandemic has disrupted cancer care, causing delays in diagnosis and treatment, exacerbating existing healthcare disparities, and negatively affecting patient outcomes.
Conclusions: SARS-CoV-2 impacts cancer progression through a combination of direct and indirect mechanisms. Future studies should focus on identifying vulnerable cancer patient populations, clarifying molecular pathways connecting COVID-19 and cancer progression, and developing tailored therapeutic approaches to mitigate these risks.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>55</FPAGE>
			<TPAGE>62</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/12024/08/132024/06/212024/07/23
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/5/2
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/292024/09/172024/09/132024/09/14
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/24
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Muhammad</Name>
				<MidName></MidName>
				<Family>Waqas</Family>
				<NameE>Muhammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Waqas</FamilyE>
				<Organizations>
				<Organization>Division of Science and Technology, Department of Zoology, University of Education, Lahore, Pakistan.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>waqassiddique614@gmail.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Razia</Name>
				<MidName></MidName>
				<Family>Bashir</Family>
				<NameE>Razia</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Bashir</FamilyE>
				<Organizations>
				<Organization>Division of Science and Technology, Department of Zoology, University of Education, Lahore, Pakistan.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Lea</Name>
				<MidName></MidName>
				<Family>Nohra</Family>
				<NameE>Lea</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nohra</FamilyE>
				<Organizations>
				<Organization>Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Stephen</Name>
				<MidName></MidName>
				<Family>Feranmi Adeyemo</Family>
				<NameE>Stephen</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Feranmi Adeyemo</FamilyE>
				<Organizations>
				<Organization>Division of Medical Artificial Intelligence, Helix Biogen Institute, Ogbomosho, Oyo State, Nigeria, Nigeria.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Duru</Name>
				<MidName></MidName>
				<Family>Confidence</Family>
				<NameE>Duru</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Confidence</FamilyE>
				<Organizations>
				<Organization>Department of Veterinary Biochemistry and Physiology, University of Abuja, Nigeria.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Muhammad</Name>
				<MidName></MidName>
				<Family>Tayyab</Family>
				<NameE>Muhammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Tayyab</FamilyE>
				<Organizations>
				<Organization>Division of Science and Technology, Department of Chemistry, University of Education, Lahore, Pakistan.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>ur Sami</Name>
				<MidName></MidName>
				<Family>Rahman</Family>
				<NameE>ur Sami</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Rahman</FamilyE>
				<Organizations>
				<Organization>Division of Science and Technology, Department of Zoology, University of Education, Lahore, Pakistan.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>SARS-CoV-2</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>COVID-19</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Cancer</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>The Positive Impact of Virulence Genes in Bacterial Pathogenicity and Colonization on the Large Bowel in Colorectal Cancer Patients</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>Colorectal Cancer (CRC) is the third most common cancer around the world. Among the various factors associated with the development of CRC, bacterial infection and related toxins are considered the most critical risk factors. Several virulence genes, including fimC, cnf1, vat1, hlyD, clbB, clbN, feoA, feoB, fyuA, iroN, ireA, iutA, KpsMT (k1), KpsMTII, and KpsMTIII, have been found to have a more significant influence on the pathogenicity of the bacteria. This research aimed to assess the possible position performed through a few virulence genes in E. coli isolated from the intestinal tissues&#39; biopsies of patients with colorectal cancer. Using microbial and biochemical methods, this study isolated 82 samples of E. coli from all of the 170 biopsies obtained from patients suffering from CRC, inflammatory bowel disease, and normal individuals. Then, the frequency of 15 virulence genes was assessed by applying PCR. The obtained results indicated that two types of bacterial genes as following are more likely to be involved in CRC development: clbB and clbN genes, which are associated with the colibactin polyketide synthesis system, as well as KpsMTIII gene, which is involved in polysaccharide capsule synthesis. In precis, these consequences suggest that the superiority of E. coli containing clbB, clbN, and KpsMTIII plays an extensive role in the inflammation and, therefore, the occurrence of CRC.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>63</FPAGE>
			<TPAGE>69</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/12024/08/132024/06/212024/07/232024/06/19
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/3/30
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/292024/09/172024/09/132024/09/142024/09/3
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/13
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Mohammad</Name>
				<MidName></MidName>
				<Family>Khalilolahi</Family>
				<NameE>Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Khalilolahi</FamilyE>
				<Organizations>
				<Organization>Department of Microbiology, Islamic Azad University, North Tehran Branch, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>pooya_780@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Fatemeh</Name>
				<MidName></MidName>
				<Family>Ashrafi</Family>
				<NameE>Fatemeh</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Ashrafi</FamilyE>
				<Organizations>
				<Organization>Department of Microbiology, Islamic Azad University, North Tehran Branch, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>mnfa.ashrafi@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Arash</Name>
				<MidName></MidName>
				<Family>Moradi</Family>
				<NameE>Arash</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Moradi</FamilyE>
				<Organizations>
				<Organization>Departments of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email></Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Jean-Philippe</Name>
				<MidName></MidName>
				<Family>Nougayre`de</Family>
				<NameE>Jean-Philippe</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Nougayre`de</FamilyE>
				<Organizations>
				<Organization>INRA, UMR1225, F-31076 Toulouse, France, and Universite´ de Toulouse, ENVT, UMR1225, F-31076 Toulouse, France</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>jean-philippe.nougayrade@inrae.fr</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Shahla</Name>
				<MidName></MidName>
				<Family>Mohammad ganji</Family>
				<NameE>Shahla</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Mohammad ganji</FamilyE>
				<Organizations>
				<Organization>Departments of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>shahla@nigeb.ac.ir</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Escherichia coli (E. coli)</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Intestine's inflammatory disease (IBD)</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Virulence genes</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Colorectal cancer (CRC)</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>


	<ARTICLE> 
		<TitleF>Microbial Allies: How Gut Microbiota Influence the Effectiveness of Immune Checkpoint Inhibitors</TitleF>
		<TitleE></TitleE>
		<TitleLang_ID>2</TitleLang_ID>
		<ABSTRACTS>
			<ABSTRACT>
			<Language_ID>2</Language_ID>
			<CONTENT>The importance of the gut microbiota in human health and disease has been known for a long time. Current investigations involving preclinical and clinical studies have presented numerous lines of evidence indicating that gut microbiota can influence the effectiveness of cancer immunotherapies, particularly immune checkpoint inhibitors (ICIs). The gut microbiota can alter the immune response in the tumor microenvironment (TME) by engaging with innate and adaptive immune cells. Notably, one of the primary methods by which the gut microbiota modulates antitumor immunity is through the production of metabolites, which are small molecules capable of traveling from the gut to other parts of the body and influencing local and systemic antitumor immune responses. This exploration of mechanisms has yielded valuable insights for developing microbiota-based therapeutic strategies such as fecal microbiota transplantation (FMT), probiotics, engineered microbiomes, and specific microbial metabolites. In this review, we explored several possible interventions that could enhance the efficacy of ICIs, thereby potentially restoring or augmenting patient responses to these therapeutic agents.</CONTENT>
			</ABSTRACT>
		</ABSTRACTS>

		<PAGES>
			<PAGE>
			<FPAGE>70</FPAGE>
			<TPAGE>85</TPAGE>
			</PAGE>
		</PAGES>

		<RECEIVE_DATE>
			2024/07/312024/08/132024/07/22024/07/222024/07/12024/08/132024/06/212024/07/232024/06/192024/07/4
		</RECEIVE_DATE>

		<RECEIVE_DATE_FA>
			1403/4/14
		</RECEIVE_DATE_FA>

		<ACCEPT_DATE>
			2024/09/232024/09/232024/09/172024/09/232024/08/292024/09/172024/09/132024/09/142024/09/32024/09/12
		</ACCEPT_DATE>

		<ACCEPT_DATE_FA>
			1403/6/22
		</ACCEPT_DATE_FA>

		<AUTHORS>
			<AUTHOR>
				<Name>Hamed</Name>
				<MidName></MidName>
				<Family>Azhdari Tehrani</Family>
				<NameE>Hamed</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Azhdari Tehrani</FamilyE>
				<Organizations>
				<Organization>Department of Hematology-Medical oncology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>hamed_azhdari@sbmu.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Amir-Mohammad</Name>
				<MidName></MidName>
				<Family>Yousefi</Family>
				<NameE>Amir-Mohammad</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Yousefi</FamilyE>
				<Organizations>
				<Organization>Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>amirmm.yousefi@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Sina</Name>
				<MidName></MidName>
				<Family>Salari</Family>
				<NameE>Sina</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Salari</FamilyE>
				<Organizations>
				<Organization>Department of Hematology-oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>s.salari@sbmu.ac.ir</Email>
				</EMAILS>
			</AUTHOR>

			<AUTHOR>
				<Name>Davood</Name>
				<MidName></MidName>
				<Family>Bashash</Family>
				<NameE>Davood</NameE>
				<MidNameE></MidNameE>
				<FamilyE>Bashash</FamilyE>
				<Organizations>
				<Organization>Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Organization>
				</Organizations>
				<Countries>
				<Country></Country>
				</Countries>
				<EMAILS>
				<Email>david_5980@yahoo.com</Email>
				</EMAILS>
			</AUTHOR>
		</AUTHORS>


		<KEYWORDS>
			<KEYWORD>
				<KeyText>Gut microbiota</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Immunotherapy</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Immune checkpoint inhibitors</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>ICIs</KeyText>
			</KEYWORD>

			<KEYWORD>
				<KeyText>Cancer</KeyText>
			</KEYWORD>
		</KEYWORDS>

		<REFRENCES>
			<REFRENCE>
				<REF>Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Frontiers in Oncology. 2021;11:633032.##Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annual Review of Pathology: Mechanisms of Disease. 2021;16:223-49.##Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients. Cancer medicine. 2018;7(3):746-56.##Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA. Targeting the gut and tumor microbiota in cancer. Nature medicine. 2022;28(4):690-703.##Ijsselsteijn R, Jansen JG, de Wind N. DNA mismatch repair-dependent DNA damage responses and cancer. DNA repair. 2020;93:102923.##Mestrallet G, Brown M, Bozkus CC, Bhardwaj N. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Frontiers in Immunology. 2023;14:1210164.##Yang Y, Li X, Ma Z, Wang C, Yang Q, Byrne-Steele M, et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nature communications. 2021;12(1):525.##Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer. 2021;12(9):2735.##Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ, editors. Emerging concepts in PD-1 checkpoint biology. Seminars in immunology; 2021: Elsevier.##Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nature reviews Drug discovery. 2011;10(6):411-2.##Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proceedings of the National Academy of Sciences of the United States of America. 2023;120(31):e2300895120.##Wong SK, Beckermann KE, Johnson DB, Das S. Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert opinion on biological therapy. 2021;21(12):1623-34.##Keytruda (pembrolizumab) prescribing information [Internet] Whitehouse Station (NJ): Merck &#38; Co., Inc; 2014. [cited 2014 Oct 23]. 12p. Available from: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. [Google Scholar].##Opdivo (nivolumab) prescribing information [Internet]. Princeton (NJ): Bristol-Myers Squibb Company; 2015. [cited 2015 Jan 27]. 8p. Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf. [Google Scholar].##Zhang Q, Huo G-w, Zhang H-z, Song Y. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis. Open Medicine. 2020;15(1):447-56.##Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. American Society of Clinical Oncology; 2015.##Mok TS, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2019;393(10183):1819-30.##Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. 2019.##Tang Q, Li S, Huang G, Liu H. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. International Immunopharmacology. 2023;119:110158.##Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer. Cancer Medicine. 2023;12(5):5372-83.##Fasano M, Della Corte CM, Di Liello R, Barra G, Sparano F, Viscardi G, et al. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. Esmo Open. 2020;5(5):e000753.##Walker AW, Hoyles L. Human microbiome myths and misconceptions. Nature Microbiology. 2023;8(8):1392-6.##Barone M, D'Amico F, Brigidi P, Turroni S. Gut microbiome-micronutrient interaction: The key to controlling the bioavailability of minerals and vitamins? Biofactors. 2022;48(2):307-14.##Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell research. 2020;30(6):492-506.##Borbet TC, Pawline MB, Li J, Ho ML, Yin YS, Zhang X, et al. Disruption of the early-life microbiota alters Peyer's patch development and germinal center formation in gastrointestinal-associated lymphoid tissue. Iscience. 2023;26(6).##Sun C-Y, Yang N, Zheng Z-L, Liu D, Xu Q-L. T helper 17 (Th17) cell responses to the gut microbiota in human diseases. Biomedicine &#38; Pharmacotherapy. 2023;161:114483.##Bugl S, Wirths S, Müller MR, Radsak MP, Kopp HG. Current insights into neutrophil homeostasis. Annals of the New York Academy of Sciences. 2012;1266(1):171-8.##Strowig T, Thiemann S, Diefenbach A. Microbiome and gut immunity: innate immune cells. The Gut Microbiome in Health and Disease. 2018:103-18.##Jiménez-Saiz R, Anipindi VC, Ellenbogen Y, Koenig JF, Chu DK, Ask K, et al. Microbial regulation of enteric eosinophils and its impact on tissue remodeling and Th2 immunity. Frontiers in Immunology. 2020;11:500585.##Lee C, Lee H, Park JC, Im S-H. Microbial components and effector molecules in T helper cell differentiation and function. Immune Network. 2023;23(1).##Mashiah J, Karady T, Fliss‐Isakov N, Sprecher E, Slodownik D, Artzi O, et al. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis. Immunity, inflammation and disease. 2022;10(3):e570.##Fang Z, Li L, Zhao J, Zhang H, Lee Y-K, Lu W, et al. Bifidobacteria adolescentis regulated immune responses and gut microbial composition to alleviate DNFB-induced atopic dermatitis in mice. European Journal of Nutrition. 2020;59:3069-81.##Kwon M-S, Roh SW, Choi H-J. Lactobacillus sakei WIKIM30 ameliorates atopic dermatitis-like skin lesions by inducing regulatory T cells and altering gut microbiota structure in mice. Frontiers in immunology. 2018;9:402989.##Li T, Ma X, Wang T, Tian W, Liu J, Shen W, et al. Clostridium butyricum Inhibits the Inflammation in Children with Primary Nephrotic Syndrome by Regulating Th17/Tregs Balance via Gut-Kidney Axis. 2023.##Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Frontiers in immunology. 2015;6:168417.##Amy IY, Zhao L, Eaton KA, Ho S, Chen J, Poe S, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell reports. 2020;31(1).##Pabst O, Nowosad CR, editors. B cells and the intestinal microbiome in time, space and place. Seminars in Immunology; 2023: Elsevier.##Nowosad CR, Mesin L, Castro TB, Wichmann C, Donaldson GP, Araki T, et al. Tunable dynamics of B cell selection in gut germinal centres. Nature. 2020;588(7837):321-6.##Li H, Limenitakis JP, Greiff V, Yilmaz B, Schären O, Urbaniak C, et al. Mucosal or systemic microbiota exposures shape the B cell repertoire. Nature. 2020;584(7820):274-8.##De Filippis F, Paparo L, Nocerino R, Della Gatta G, Carucci L, Russo R, et al. Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance. Nature Communications. 2021;12(1):5958.##Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-84.##Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-9.##Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M, Karpinets T, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.##Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7.##Schaupp L, Muth S, Rogell L, Kofoed-Branzk M, Melchior F, Lienenklaus S, et al. Microbiota-induced type I interferons instruct a poised basal state of dendritic cells. Cell. 2020;181(5):1080-96. e19.##Kalafati L, Kourtzelis I, Schulte-Schrepping J, Li X, Hatzioannou A, Grinenko T, et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell. 2020;183(3):771-85. e12.##Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184(21):5338-56. e21.##Deng H, Li Z, Tan Y, Guo Z, Liu Y, Wang Y, et al. A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages. Scientific reports. 2016;6(1):29401.##Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022-37. e14.##Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. Journal of Thoracic Oncology. 2019;14(8):1378-89.##Qiu Y, Jiang Z, Hu S, Wang L, Ma X, Yang X. Lactobacillus plantarum enhanced IL-22 production in natural killer (NK) cells that protect the integrity of intestinal epithelial cell barrier damaged by enterotoxigenic Escherichia coli. International Journal of Molecular Sciences. 2017;18(11):2409.##Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Science Advances. 2021;7(37):eabg5016.##Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nature reviews Clinical oncology. 2021;18(2):85-100.##Nicolai CJ, Wolf N, Chang I-C, Kirn G, Marcus A, Ndubaku CO, et al. NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Science immunology. 2020;5(45):eaaz2738.##Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602-9.##Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(7741):600-5.##Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of Oncology. 2017;28(6):1368-79.##Mager LF, Burkhard R, Pett N, Cooke NC, Brown K, Ramay H, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369(6510):1481-9.##Kikuchi T, Mimura K, Ashizawa M, Okayama H, Endo E, Saito K, et al. Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers. Cancer Immunology, Immunotherapy. 2020;69:23-32.##Jain T, Dudeja V. New insights into the cancer-microbiome-immune axis: decrypting a decade of discoveries. Frontiers in immunology. 2021;12:622064.##Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-8.##Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Frontiers in Microbiology. 2020;11:814.##Coutzac C, Jouniaux J-M, Paci A, Schmidt J, Mallardo D, Seck A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nature communications. 2020;11(1):2168.##Dees KJ, Koo H, Humphreys JF, Hakim JA, Crossman DK, Crowley MR, et al. Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma. Neuro-oncology advances. 2021;3(1):vdab023.##Gao G, Ma T, Zhang T, Jin H, Li Y, Kwok LY, et al. Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota. Front Immunol. 2021;12:772532.##Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, et al. A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. Cancer Discov. 2022;12(4):1070-87.##Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023.##Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. Journal of Clinical Oncology. 2022.##Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-79.##Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. European urology. 2020;78(2):195-206.##Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature medicine. 2022;28(2):315-24.##Goubet A-G, Wheeler R, Fluckiger A, Qu B, Lemaître F, Iribarren K, et al. Multifaceted modes of action of the anticancer probiotic Enterococcus hirae. Cell Death &#38; Differentiation. 2021;28(7):2276-95.##Wu Q, Liu J, Wu S, Xie X. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Int Immunopharmacol. 2021;92:107303.##Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670.##Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncology. 2019;5(12):1774-8.##Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, et al. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. Oncologist. 2020;25(1):55-63.##Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.##Ademe M. Benefits of fecal microbiota transplantation: A comprehensive review. The Journal of Infection in Developing Countries. 2020;14(10):1074-80.##Quraishi MN, Widlak M, Bhala Na, Moore D, Price M, Sharma N, et al. Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary pharmacology &#38; therapeutics. 2017;46(5):479-93.##Biancheri P, Divekar D, Watson AJ. Could fecal transplantation become part of PD-1-based immunotherapy, due to effects of the intestinal microbiome? Gastroenterology. 2018;154(6):1845-7.##Genton L, Lazarevic V, Stojanovic O, Spiljar M, Djaafar S, Koessler T, et al. Metataxonomic and metabolic impact of fecal microbiota transplantation from patients with pancreatic cancer into germ-free mice: A pilot study. Frontiers in cellular and infection microbiology. 2021;11:752889.##Wang Y, Varatharajalu K, Shatila M, Thomas A, Campbell M, Msaouel P, et al. S227 First-Line Treatment of Fecal Microbiota Transplantation for Immune-Mediated Colitis. Official journal of the American College of Gastroenterology| ACG. 2023;118(10S):S170.##Rapoport EA, Baig M, Puli SR. Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis. Annals of Gastroenterology. 2022;35(2):150.##Nguyen TL, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech. 2015;8(1):1-16.##Ciernikova S, Sevcikova A, Drgona L, Mego M. Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023:188990.##Canale FP, Basso C, Antonini G, Perotti M, Li N, Sokolovska A, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. 2021;598(7882):662-6.##Bevilacqua A, Campaniello D, Speranza B, Racioppo A, Sinigaglia M, Corbo MR. An Update on Prebiotics and on Their Health Effects. Foods. 2024;13(3):446.##Taper HS, Roberfroid MB. Possible adjuvant cancer therapy by two prebiotics-inulin or oligofructose. In vivo. 2005;19(1):201-4.## ##</REF>
			</REFRENCE>
		</REFRENCES>

	</ARTICLE>

</ARTICLES>

</JOURNAL>
</XML>
